liveBook · Manning

Privileged structure

As explained in Build AI Drug Discovery Pipelines

A privileged structure is a molecular scaffold that occurs in active compounds and can bind productively to multiple protein targets.

A privileged structure is a molecular scaffold found repeatedly in active compounds and capable of productive binding to multiple protein targets. Medicinal chemists use these historically active scaffolds to reduce the risk of exploring entirely unknown chemical territory during drug discovery. section 1.1.2

Benzodiazepine core

The benzodiazepine core appears in diazepam and alprazolam, which bind GABA receptors. Benzodiazepine-derived compounds have also shown activity against CCK receptors, HIV-1 reverse transcriptase, and various GPCRs. section 1.1.2

Account for two important trade-offs:

  • Treat activity across multiple targets as potentially promiscuous, because unwanted binding can cause side effects. section 1.1.2
  • Expect related compounds to face greater patenting difficulty because privileged structures have been extensively researched and used in patented drugs. section 1.1.2

How Build AI Drug Discovery Pipelines covers it

How deep it goes
Defines the scaffold concept and illustrates multi-target binding, but does not explain computational identification or molecular binding mechanisms.
Examples
Uses the benzodiazepine core, diazepam, alprazolam, GABA receptors, CCK receptors, HIV-1 reverse transcriptase, and GPCRs.
What you can do after
Evaluate privileged scaffolds as risk-mitigation starting points while anticipating promiscuity, side effects, and patent constraints.
How it connects
Connects molecular scaffolds with medicinal chemistry, protein targets, promiscuity, side effects, and patenting.

Related concepts

This explainer was generated by Manning's knowledge graph from the text of Build AI Drug Discovery Pipelines. The section links point to the parts of the book it draws on.